VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

MERS England S1 subunit protein vaccine
Vaccine Information
  • Vaccine Name: MERS England S1 subunit protein vaccine
  • Target Pathogen: MERS-CoV
  • Target Disease: Middle East Respiratory Syndrome (MERS)
  • Type: Subunit vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse, rhesus monkey
  • Antigen: S1 subunit of S from MERS-CoV. (Wang et al., 2015)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: A DNA vaccine constructed from a plasmid vaccines that encoded S1 subunit only. (Wang et al., 2015)
Host Response

Mouse Response

Macaque Response

  • Host Strain: Macaca mulatta (Wang et al., 2015)
  • Host gender: Male and Female (Wang et al., 2015)
  • Vaccination Protocol: Six NHPs in the protein-only group were injected with 100 μg of MERS-CoV S1 protein and AlPO4 adjuvant at weeks 0 and 8. (Wang et al., 2015)
  • Immune Response: Induced high level of neutralizing antibodies (IgG1). Sera from immunized NHPs blocked mAbs targeted to the RBD and non-RBD S1 subunit, but not the S2 subunit. (Wang et al., 2015)
  • Challenge Protocol: Animals were administered 100 μg of MERS-CoV S1 protein and AlPO4 adjuvant at weeks 0 and 8, then challenged with Jordan N3 strain of MERS-CoV 19 weeks after imunization at 3.1 x 106, 3.6 x 106, and 3.4 x 106 p.f.u. (Wang et al., 2015)
  • Efficacy: protected (Wang et al., 2015)
References
Wang et al., 2015: Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS. Evaluation of candidate vaccine approaches for MERS-CoV. Nature communications. 2015; 6; 7712. [PubMed: 26218507].